Respiratory Syncytial Virus Treatment and Prevention in Elderly Patients

Introduction to RSV Treatment and Prevention

• The American College of Physicians and other medical societies recommend that treatment for RSV in elderly patients is primarily supportive care, as there are no specific FDA-approved antiviral treatments for RSV in adults, while vaccination is now recommended as the primary preventive strategy for this high-risk population 1, 2

Supportive Care Management

• For elderly patients with underlying respiratory conditions such as COPD or asthma, management of exacerbations according to standard protocols is essential, as recommended by the American Thoracic Society 1, 3
• Functional status assessment should be incorporated into care plans, as RSV infection can cause significant functional decline in elderly patients, particularly those with pre-existing frailty, according to the American Geriatrics Society 1, 3

Diagnostic Considerations

• Nucleic acid-based testing (RT-PCR) is recommended for diagnosis of RSV in elderly patients, particularly those at high risk for severe disease, as suggested by the Infectious Diseases Society of America 2
• Testing is especially important in immunocompromised elderly patients, including those with solid organ or hematopoietic stem cell transplants, hematological malignancies or solid tumors, chronic immunosuppressive therapy, or HIV infection, as recommended by the Centers for Disease Control and Prevention 2, 3

Prevention Through Vaccination

• Two RSV vaccines are now available and recommended for elderly patients, including RSVPreF3 and RSVpreF, for adults ≥60 years and adults 50-59 years at increased risk, as recommended by the American College of Physicians and the Centers for Disease Control and Prevention 4, 5
• Vaccination is particularly important for all adults aged ≥75 years regardless of comorbidities, adults aged 60-74 years with risk factors, and residents of nursing homes or long-term care facilities, as recommended by the National Foundation for Infectious Diseases 6
• Vaccination should preferably be administered between September and November, before or early in the RSV season, and a single dose is recommended, which can be co-administered with seasonal influenza vaccine at different injection sites, as recommended by the Centers for Disease Control and Prevention 6

Clinical Outcomes

• The mortality rate from RSV in hospitalized elderly patients can be significant (4.6% in those aged 60-74 years and 6.1% in those ≥75 years), as reported by the American Journal of Respiratory and Critical Care Medicine 1, 3
• Elderly patients with dementia have higher mid- to long-term mortality following RSV infection (aHR = 1.86), according to the American Geriatrics Society 3
• Functional decline following RSV infection can be prolonged, particularly in frail elderly patients from skilled nursing facilities, as reported by the Journal of the American Geriatrics Society 3

RSV Infection Management in Elderly Patients

Risk Factors and Outcomes

• Patients on systemic corticosteroids are at highest risk for hospitalization due to RSV compared to other patients with underlying conditions 7, 8
• Elderly patients (≥60 years) with RSV infection who are on systemic corticosteroids have been identified as having the highest risk for severe outcomes 9
• Older adults (>60 years) are at increased risk for serious complications of RSV including respiratory failure 9, 10
• Older adults (>60 years) are at increased risk for serious complications of RSV including pneumonia 9, 10
• Mortality rates for RSV infection in elderly patients are around 2-5% 9

Prevention and Vaccination

• All adults aged ≥60 years are recommended to receive RSV vaccination according to some guidelines 9, 11
• RSV vaccination is recommended for adults aged ≥75 years regardless of comorbidities, and adults aged 60-74 years with risk factors 9, 11
• Currently available RSV vaccines include RSVPreF3 OA (Arexvy) from GlaxoSmithKline 9, RSVpreF (Abrysvo) from Pfizer 9, and mRESVIA (mRNA-1345) 9

High-Risk Populations

• Risk factors that further increase severity in elderly patients include advanced age (≥75 years) 10, diabetes 12, chronic kidney disease 12, immunocompromised status 12, and residence in nursing homes or long-term care facilities 10

RSV Treatment in Adults with Immunocompromise or High-Risk Conditions

Special Populations Requiring Consideration

• For severely immunocompromised adults, off-label ribavirin (aerosolized or oral) combined with intravenous immunoglobulin has been used based on observational data showing improved survival, although the evidence remains limited to observational studies and it is not FDA-approved for this indication 13
• Adults with chronic cardiopulmonary disease (COPD, asthma, heart failure) are at high risk for severe outcomes and warrant aggressive supportive care 14

Immune System Compromise with Corticosteroids and RSV Infection

Understanding the Immunosuppressive Risk

• The American College of Rheumatology guidance emphasizes that glucocorticoids may increase the risk of secondary infection and delay viral clearance for respiratory viruses including RSV, with a significant increase in hospitalization risk in patients with viral respiratory infections taking prednisone >10mg daily 15, 16
• Patients on systemic corticosteroids, such as prednisone 20mg daily, represent a high-risk group for RSV hospitalization, with an increased risk of severe outcomes, including progression to lower respiratory tract disease, hospitalization, and mortality 15, 16

Clinical Implications for RSV Infection

• Glucocorticoids may delay viral clearance in RSV and other respiratory viral infections, with the American College of Rheumatology recommending careful consideration of the risks and benefits of corticosteroid use in patients with RSV infection 15, 16
• The American Academy of Pediatrics explicitly recommends against routine corticosteroid use in RSV management, with adult data showing no benefit and potential harm 15, 16

Management Algorithm

• The American College of Rheumatology recommends continuing prednisone at the lowest effective dose to control the underlying disease in patients with life-threatening or organ-threatening conditions, while considering dose reduction or temporary discontinuation in patients with non-urgent indications 15, 16
• Patients on chronic corticosteroids, even for a short duration, may require stress-dose corticosteroids during acute illness to prevent adrenal crisis, with the FDA warning that adrenocortical insufficiency may result from too rapid withdrawal 15, 16

Prevention Considerations for Future

• RSV vaccination is now available and recommended for adults ≥60 years (or 50-59 years with risk factors including immunosuppression), with consideration for vaccination once the acute infection resolves to prevent future episodes 17

RSV Infection Risk and Management in Immunocompromised Patients

Introduction to RSV Risk

• Patients taking 15mg of prednisone daily face significantly elevated risk for severe RSV infection, with immunosuppressed individuals showing hospitalization rates of 1,288-1,562 per 100,000 and 90-day mortality rates reaching 52.8% among those requiring ICU admission 18

Understanding the Immunosuppressive Risk

• Moderate immunosuppression from corticosteroids is explicitly recognized as a major risk factor for severe RSV disease, with the CDC's Advisory Committee on Immunization Practices specifically listing "moderate or severe immune compromise" as a high-risk category warranting RSV vaccination in adults aged 60-74 years 19, 20

Clinical Outcomes and Mortality Risk

• 90-day mortality among immunocompromised ICU patients with RSV reaches 52.8% 18, 21
• ICU admission rates are 36% among immunocompromised patients hospitalized with RSV 18, 21
• Hospitalization rates for immunosuppressed individuals range from 1,288 to 1,562 per 100,000 18, 21

Risk Stratification Algorithm

• Age ≥60 years (especially ≥75 years) is a high-risk feature requiring immediate vaccination consideration 19, 20
• Underlying chronic lung disease (COPD, asthma, interstitial lung disease) is a high-risk feature requiring immediate vaccination consideration 19, 20
• Chronic cardiovascular disease (heart failure, coronary artery disease) is a high-risk feature requiring immediate vaccination consideration 19, 20
• Chronic kidney disease or end-stage renal disease is a high-risk feature requiring immediate vaccination consideration 18, 21
• Diabetes with complications is a high-risk feature requiring immediate vaccination consideration 19, 20
• Frailty or residence in nursing home is a high-risk feature requiring immediate vaccination consideration 19, 20

Management Recommendations

• The CDC recommends RSV vaccination for all adults ≥75 years on any immunosuppression 19, 20
• The CDC recommends RSV vaccination for adults aged 60-74 years with moderate immunosuppression (including chronic corticosteroid use) 19, 20
• If RSV infection occurs, treatment is primarily supportive, and monitoring closely for progression to lower respiratory tract disease is crucial 18, 21
• The American College of Cardiology is not mentioned in the article, however the CDC's Advisory Committee on Immunization Practices recommends vaccination for high risk individuals 19, 20
• Aggressive supportive care with oxygen supplementation as needed, and considering stress-dose corticosteroids only if the patient develops severe illness requiring ICU admission, while continuing the baseline 15mg prednisone dose to control the underlying disease and prevent adrenal crisis 18, 21

Antibiotic Management in Elderly Hospitalized Patients with Respiratory Syncytial Virus (RSV)

1. Indications for Initiating Antibiotics

• Antibiotics should be started only when documented bacterial co‑infection is confirmed by positive cultures from blood, sputum, or bronchoscopy specimens. [22][23]
• In the presence of strong clinical evidence of secondary bacterial pneumonia, antibiotics are warranted if a new infiltrate appears on chest radiography together with purulent sputum. 22
• A predominant bacterial morphotype on Gram stain of respiratory specimens also supports the need for antibiotics. 23
• Clinical deterioration after an initial period of improvement (e.g., new fever or worsening respiratory status) suggests a superimposed bacterial infection and justifies antibiotic therapy. 22
• For high‑risk elderly patients with severe presentation (e.g., pneumonia plus comorbidities such as diabetes, heart failure, moderate‑severe COPD, liver or renal disease), empiric antibiotics may be initiated while awaiting diagnostic confirmation, given an observed in‑hospital mortality of approximately 6 %. 23

2. Recommended Antibiotic Regimens (When Indicated)

All recommendations are based on the 2011 Clinical Microbiology and Infection evidence. 22

3. Essential Diagnostic Steps Prior to Antibiotic Use

• Obtain two sets of blood cultures from every hospitalized patient with confirmed RSV before starting antibiotics. 23
• Perform sputum Gram stain and culture when purulent sputum is available to identify bacterial pathogens. 23
• Acquire a chest X‑ray to evaluate for new infiltrates suggestive of bacterial pneumonia. 22

4. Risk Stratification and Expected Outcomes

• Age ≥ 75 years is associated with a 30‑day mortality hazard ratio of 2.85, indicating markedly higher risk. 24
• Overall mortality rates range from 4.6 % in patients aged 60–74 to 6.1 % in those ≥ 75 years. 24

5. Antibiotic Stewardship Recommendations

• Re‑evaluate the need for antibiotics within 48–72 hours after RSV confirmation and after culture results become available; discontinue if no bacterial infection is identified. 22
• Avoid prescribing antibiotics solely on the basis of fever, elevated white‑blood‑cell count, or nonspecific respiratory symptoms, as these are common in viral RSV infection.

All facts above are derived from peer‑reviewed evidence (Clinical Microbiology and Infection, 2011; Pulmonology, 2025) and reflect the current consensus on managing bacterial co‑infection in elderly patients hospitalized with RSV.

RSV Vaccination Recommendations for Older Adults

Eligibility

• Adults aged ≥ 75 years should receive a single lifetime dose of an RSV vaccine, regardless of comorbidities, because this age group experiences markedly higher rates of hospitalization, severe disease, and mortality from RSV. 25

Vaccine Options

• Two licensed RSV vaccines are available for this population: the recombinant subunit vaccine RSVPreF3 (brand name Arexvy) and the RSVpreF vaccine (brand name Abrysvo), each administered as a single intramuscular injection. 25

Efficacy and Duration of Protection

• In pivotal clinical trials, RSVPreF3 achieved ≈ 82.6 % efficacy against RSV‑associated lower respiratory tract disease and ≈ 94.1 % efficacy against severe RSV disease during the first RSV season after vaccination. 25
• A single dose provides protection that persists for at least two consecutive RSV seasons. 25

RSV Vaccination Recommendations for Older Adults

Eligibility Criteria

• All adults aged ≥ 75 years should receive a single dose of an RSV vaccine regardless of comorbidities, because they have markedly higher rates of hospitalization, severe disease, and 30‑day mortality (hazard ratio ≈ 2.85). 26, 27
• Adults aged 60–74 years who have any of the following risk factors—chronic obstructive pulmonary disease, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, or residence in a long‑term‑care facility—should be vaccinated against RSV. 26, 27
• Adults aged 50–59 years with comparable risk factors should receive RSVPreF3 (Arexvy), the only RSV vaccine currently approved for this age group. 26

Vaccine Efficacy

• The recombinant protein subunit vaccine RSVPreF3 (Arexvy, GSK) demonstrated 82.6 % efficacy against RSV‑associated lower respiratory‑tract disease and 94.1 % efficacy against severe disease during the first season, with protection persisting for at least three seasons. 26
• The bivalent recombinant vaccine RSVpreF (Abrysvo, Pfizer) showed 88.9 % efficacy against RSV‑associated lower respiratory‑tract infection with ≥ 3 symptoms in the first season, with protection maintained for at least two seasons. 26

Administration Timing and Co‑administration

• The RSV vaccine should be administered preferably between September and November, i.e., before or at the onset of the RSV season, to achieve maximal protective benefit. 26, 27
• Co‑administration of the RSV vaccine with the seasonal influenza vaccine is acceptable when given at separate injection sites. 26, 27

Prioritization When Vaccine Supply Is Limited

• First priority: adults aged ≥ 75 years.
• Second priority: adults aged ≥ 50 years with multiple comorbidities.
• Third priority: residents of long‑term‑care facilities. 26, 27